Piper Sandler analyst Jason Bednar upgraded Sotera Health (SHC) to Overweight from Neutral with a price target of $24, up from $17. The firm says end market demand has improved for the “all-important” Sterigenics franchise. Piper has confidence in the company’s 2026 outlook as its “de-risking” continues.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SHC:
- Sotera Health initiated with an Outperform at William Blair
- Sotera Health: Integrated Market Leadership, Easing Litigation Overhang, and Valuation Upside Support Buy Rating
- Sotera Health 16.2M share Block Trade priced at $16.50
- BMO Capital’s Buy Rating on Sotera Health: Positive Outlook Amid Growth Resurgence and Strategic Strengths
- Sotera Health initiated with an Outperform at BMO Capital